经皮迷走神经刺激治疗糖尿病患者胃肠道症状:一项随机、双盲、假刺激对照、多中心试验
这项随机、双盲、假刺激对照、多中心试验纳入丹麦三个Steno糖尿病中心的1型或2型糖尿病伴自主神经病变和胃肠道症状的成人,比较颈部经皮迷走神经刺激(tVNS)与假刺激对胃肠道症状的影响。结果显示,活性tVNS与假刺激在GCSI和GSRS症状评分改善上无显著差异,胃排空时间在活性组增加,tVNS耐受性良好。结论认为颈部tVNS与假刺激相比未改善该类患者的胃肠道症状。
要点
- 在糖尿病伴自主神经病变患者中,颈部tVNS与假刺激相比未显著改善GCSI和GSRS胃肠道症状评分。
- 研究第1阶段和第2阶段活性tVNS与假刺激的症状评分变化均无统计学显著差异。
- 活性组胃排空时间较假刺激组增加(23 min vs -19 min,p=0.04)。
核心结论
- 颈部tVNS与假刺激相比,未改善糖尿病伴自主神经病变患者的胃肠道症状。
研究设计与样本
- 随机、双盲(参与者和研究者对分配治疗设盲)、假刺激对照、多中心研究。
- 纳入来自丹麦三个Steno糖尿病中心的20-86岁1型或2型糖尿病伴胃肠道症状和自主神经病变的成人。
- 参与者按1:1随机分配接受活性或假刺激。
- 活性颈部tVNS或假刺激在两个连续研究阶段自我给药:第1阶段为1周内每日四次刺激,第2阶段为8周内每日两次刺激。
- 活性组68例随机,假刺激组77例随机;第1阶段活性组63例和假刺激组68例纳入分析,第2阶段每组各62例纳入分析。
主要发现
- 第1阶段,活性tVNS与假刺激的症状评分变化相似(GCSI:-0.26 ± 0.64 vs -0.17 ± 0.62,p=0.44;GSRS:-0.35 ± 0.62 vs -0.32 ± 0.59,p=0.77;均值 ± 标准差)。
- 第2阶段,活性刺激的平均症状下降与假刺激后观察到的相当(GCSI:-0.47 ± 0.78 vs -0.33 ± 0.75,p=0.34;GSRS:-0.46 ± 0.90 vs -0.35 ± 0.79,p=0.50)。
- 胃排空时间活性组较假刺激组增加(23 min vs -19 min,p=0.04)。
- 节段性肠道传输时间和心血管自主功能测量在治疗组间无差异(所有p>0.05)。
- tVNS耐受性良好。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Diabetic gastroenteropathy frequently causes debilitating gastrointestinal symptoms. Previous uncontrolled studies have shown that transcutaneous vagal nerve stimulation (tVNS) may improve gastrointestinal symptoms. To investigate the effect of cervical tVNS in individuals with diabetes suffering from autonomic neuropathy and gastrointestinal symptoms, we conducted a randomised, sham-controlled, double-blind (participants and investigators were blinded to the allocated treatment) study. METHODS: This study included adults (aged 20-86) with type 1 or 2 diabetes, gastrointestinal symptoms and autonomic neuropathy recruited from three Steno Diabetes Centres in Denmark. Participants were randomly allocated 1:1 to receive active or sham stimulation. Active cervical tVNS or sham stimulation was self-administered over two successive study periods: 1 week of four daily stimulations and 8 weeks of two daily stimulations. The primary outcome measures were gastrointestinal symptom changes as measured using the gastroparesis cardinal symptom index (GCSI) and the gastrointestinal symptom rating scale (GSRS). Secondary outcomes included gastrointestinal transit times and cardiovascular autonomic function. RESULTS: Sixty-eight participants were randomised to the active group, while 77 were randomised to the sham group. Sixty-three in the active and 68 in the sham group remained for analysis in study period 1, while 62 in each group were analysed in study period 2. In study period 1, active and sham tVNS resulted in similar symptom reductions (GCSI: -0.26 ± 0.64 vs -0.17 ± 0.62, p=0.44; GSRS: -0.35 ± 0.62 vs -0.32 ± 0.59, p=0.77; mean ± SD). In study period 2, active stimulation also caused a mean symptom decrease that was comparable to that observed after sham stimulation (GCSI: -0.47 ± 0.78 vs -0.33 ± 0.75, p=0.34; GSRS: -0.46 ± 0.90 vs -0.35 ± 0.79, p=0.50). Gastric emptying time was increased in the active group compared with sham (23 min vs -19 min, p=0.04). Segmental intestinal transit times and cardiovascular autonomic measurements did not differ between treatment groups (all p>0.05). The tVNS was well-tolerated. CONCLUSIONS/INTERPRETATION: Cervical tVNS, compared with sham stimulation, does not improve gastrointestinal symptoms among individuals with diabetes and autonomic neuropathy. TRIAL REGISTRATION: ClinicalTrials.gov NCT04143269 FUNDING: The study was funded by the Novo Nordisk Foundation (grant number NNF180C0052045).
引用
- Kornum DS, Bertoli D, Kufaishi H, et al. Transcutaneous vagal nerve stimulation for treating gastrointestinal symptoms in individuals with diabetes: a randomised, double-blind, sham-controlled, multicentre trial. Diabetologia. 2024. PMID: 38546822. doi:10.1007/s00125-024-06129-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。